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A. Introduction
In this program, we are examining a new approach to the design of anti-cancer drugs that is directed toward (i) improving cytotoxic action against cancer cells, (ii) reducing unwanted systemic side effects, (iii) counteracting multi-drug resistance, and (iv) targeting and destroying metastatic cells as well as tumors more effectively.
Our plan is to synthesize new drug conjugates that incorporate a specific breast cancer cell targeting component, a rapid cell membrane translocating/nuclear localization moiety, and the capability to counter multi-drug resistance mediated by P-glycoprotein and related cellular efflux pumps. The conjugates will be prepared in a few synthetic steps from available intermediates.
The goal is to demonstrate a proof-of-concept of the effectiveness of this multi-functional drug hypothesis.
Specific cancer cell-targeted compounds are being prepared from the breast cancer drug doxorubicin. This cytotoxic agent is covalently linked to a synthetic arginine-glycine-aspartic acid peptidomimetic, which recognizes and binds to ayPs integrin overexpressed on the surface of breast cancer metastatic cells and tumors. The design also incorporates the Tat peptide analog, H2N[arginine]7COOH, as a rapid cell membrane translocation and effective nuclear localization moiety. Because the targeted conjugates will be rapidly directed into the cell nucleus for efficient cytotoxic effects, the drugs may escape cytoplasmic cleansing, which is mediated by cellular efflux pumps thereby abrogating an important multi-drug resistance mechanism. The new drugs will be evaluated in breast cancer cell-lines in vitro and in vivo using human breast cancer xenografts in nude mice.
B. Body
This section describes research accomplishments to date associated with the tasks outlined in the original award application.
Taskl. Synthesize several covalent conjugates utilizing the anti-tumor drug doxorubicin, which are linked to a cell translocating/nuclear localizing arginine peptide and a selective breast cancer cell targeting ligand, as well as appropriately linked components as controls (Months 1-18)
The three-component conjugates are being assembled according to the arrangement shown below. As reported in our first annual report last year, we examined unsuccessfully a number of approaches to prepare our proposed conjugates using doxorubicin derivatives substituted at C-14. We then turned our attention to doxorubicin conjugates derivatized at the sugar amine (Scheme 1). Derivatized doxorubicin 1 was condensed, after carbodiimide activation, with the cell-translocating peptide, H2N[D-arginine]7COOH (r,) and with the peptide H2N[D-arginine]7CONH-Aminohexyl-RGDS (ry-Aminohexyl-RGDS), which incorporates the relatively low affinity ayPs integrin peptide-ligand, arginine-glycine-aspartic acid-serine (RODS). In this way, we have successfully prepared conjugates 2, 3, and 4 and have begun preliminary cell localization experiments (Task 2) as well as cytotoxicity studies (Task 3). Conjugate 4 will be derivatized with the high affinity ayPs integrin ligand 5 (Scheme 2)'. Graduate Research Assistant, Jiang Sha, has now synthesized compound 5. 
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As is apparent from Figure 1 , the parent drug, doxorubicin, is readily taken into the cells. As anticipated, DOX-hemiglutarate is not taken into the cells. This is consistent with earlier work, which has established that N-acylation of the amino sugar of doxorubicin often abrogates cell cytotoxicity^. On the other hand, attachment of either r, or r7-RGDS promotes the cancer cell uptake of the conjugates. These results are in accordance with cell cytotoxicity results (see below). The conjugates were evaluated for cytotoxicity against the ayPs expressing breast cancer cell-line MDA-MB-231 (Figure 2 ). After 24 hr exposure to the drugs, viable cells were assayed using the CyQuant^"^ cell proliferation assay (Molecular Probes, Eugene, OR). Most exciting about the results in Figure 2 is that the activity of the DOX-r7-RGDS compound is comparable to DOX itself. This is interesting and promising because DOX derivatives acylated on the carbohydrate amino group often show considerably reduced toxicity^ (e.g., note the lowered activity of DOXHemiglutarate in Figure 2 ). It appears that our cell translocating-targeting concept can even improve the activity of poorly performing DOX derivatives. 
D. Reportable Outcomes
This program supports graduate research assistant, Jiang Sha, and the results from the research will be incorporated into his dissertation. Postdoctoral research associate Hee-Kyoung Lee also assists in this effort. A manuscript is in preparation outlining the synthesis of the compounds prepared to date and their effects in breast cancer cell lines.
E. Conclusions
Research on this effort thus far has provided modified doxorubicin intermediates suitable for attachment to a cell membrane translocating functionality and ayPs integrin targeting ligands. The resulting conjugates are being evaluated breast cancer cell culture experiments in order to ascertain cytotoxicity as well as selectivity for cancer cells over normal cells.
This research is significant in that it represents the first known examples of cancer chemotherapeutic agents incorporating a drug chemically linked both to a breast cancertargeting moiety as well as a cell membrane translocating/nuclear localization functionality. The conjugates are expected to show selective targeting to breast cancer cells in preference to normal cells as well as exhibiting enhanced cancer cell cytotoxic effects. Preliminary results reported here are beginning to support the promising nature of this idea.
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